drugset / Trial / NCT03452397

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

NCT03452397 ↗

Phase 2 Completed 165 enrolled Oyster Point Pharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety and effectiveness of OC-02 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.

Timeline

Start
2018-02-27
Primary completion
2018-04-27
Completion
2018-04-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator simpinicline Small molecule 0.11 mg Intranasal
Comparator simpinicline Small molecule 0.55 mg Intranasal
Comparator simpinicline Small molecule 1.1 mg Intranasal

Indications